Johnson & Johnson

JNJ-N

Lawsuit impacts? It is facing a lawsuit on talcum powder impact on babies. These type of lawsuits can be dragged out and become an uphill battle for the company. Since this does not represent a major portion of the revenues, it should not be a long term influence. The risk is the market will redetermine the correct trading multiple and that is hard to predict. He would rather trade a medical device ETF, that includes JNJ-N.

They are a one stop shop in the consumer staple space with good demographic support. He expects dividend growth to continue. The negative is on the political side, which might hurt the healthcare space. He would definitely buy on weakness.

Just bought it Friday. A healthcare stock under pressure from law suites associated to its talcum products. A great company to own long term. Yield 2.7% (Analysts’ price target is $148.47)

Buy on a pullback, not now. Their pharma division is doing very well with products in the pipeline and wide margins. A strong balance sheet. Their dividend is almost 3% with a long history of increasing. A diversified, global name. This is quite defensive and good to hold in a weak economy. Lawsuits remain an overhang; JNJ has likely put aside some contingency money for these suits.

Always worried about large US potential lawsuits. Suffering like all the other pharma companies. Devices and consumer brands are keeping it going. Stock is not cheap. Wait for a better entry price. Lawsuits are an overhang. (Analysts’ price target is $145.00)

It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.

When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.

He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.

Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.

They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.

Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.

One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.

It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.

This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.

Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.